



Updated Monthly

November 8, 2023

---

THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding

Published by:





## Questions?

Liz Powell, Esq., MPH

[lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com)

[www.G2Gconsulting.com](http://www.G2Gconsulting.com)

  @G2Gconsulting





# GBG Report

Updated Monthly

November 8, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

## TABLE OF CONTENTS

### New Opportunities

Advanced Research Projects Agency for Health .....	2
Aging.....	2
Agriculture.....	3
Bioengineering.....	3
Cancer .....	3
Cannabis Research.....	5
Cardiovascular and Pulmonary Health.....	5
Chronic Pain & Pain Management .....	5
Cognitive and Brain Health.....	6
Combat Casualty Care.....	7
Communication Disorders.....	7
Dental and Craniofacial Research .....	7
Down Syndrome .....	8
Endocrine and Metabolic Diseases .....	8
Genomics .....	9
Health IT & Data.....	9
HIV/AIDS .....	11
Immunology & Infectious Disease .....	13
Maternal and Pediatric Health .....	13
Medical Countermeasures.....	14
Mental Health.....	14

Military Prototype Advancement Initiative.....	15
Musculoskeletal Health .....	15
Palliative Care.....	15
Patient-Centered Research .....	16
Reproductive Health.....	18
Sleep Health .....	18
Small Business Development .....	18
Social Determinants of Health .....	19
Substance Use Disorder .....	19
Therapeutics.....	20

### Recurring Opportunities

Advanced Research Projects Agency for Health .....	21
Air Force .....	21
Army.....	22
BARDA .....	23
DARPA .....	24
Defense Threat Reduction Agency.....	24
Department of Energy.....	25
National Science Foundation .....	25
Navy .....	25
<b>GBG Acronyms</b> .....	<b>26</b>



**November 17, 2023** – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 10-10:30am EST (FREE to all) and 10:30-11:00am EST (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Health Industry Forum, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

**Conference alert:** [OpMED](#) is accepting registrations for their March 25-26, 2024 event in San Antonio, TX and exhibitor space is already 50% sold out.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)</b>		
1.	ARPANET-H Network Activation Call: Stakeholder Intelligence for Advancing Clinical Trial Readiness (ACTR) Initiative (ARPA-H)  75N992-24-SN-0001	ARPA-H seeks novel clinical trial infrastructure designs that will enable rapid distribution of common clinical trial protocols across multiple geographic locations and sites in the case of a national emergency. The ACTR initiative will develop, evaluate, and integrate new tools and technologies to enable faster, less expensive, decentralized trials operating closer to/at points of care that are more representative across geography, age, gender, race, ethnicity, and socioeconomic status.  <a href="https://sam.gov/opp/7c7bb13bab544ce1a38309898a3ef946/view">https://sam.gov/opp/7c7bb13bab544ce1a38309898a3ef946/view</a>	N/A	Response: 12/1/23
		<b>AGING (2)</b>		
2.	Pre-Announcement: Nathan Shock Centers of Excellence in Basic Biology of Aging and Coordinating Center (P30/U24 CT Not Allowed) (NIH/NIA)  NOT-AG-23-062 (P30) NOT-AG-23-063 (U24)	These NOFOs will solicit applications seeking funding for leadership, training, and research activities that will aim to increase and disseminate scientific knowledge in research areas related to the biology of aging.  <a href="https://www.grants.gov/search-results-detail/350671">https://www.grants.gov/search-results-detail/350671</a> (P30) <a href="https://www.grants.gov/search-results-detail/350673">https://www.grants.gov/search-results-detail/350673</a> (U24)	TBD	Estimated post date: 2/29/24 Estimated proposal date: 6/3/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AGRICULTURE (1)</b>		
3.	Specialty Crop Research Initiative (SCRI) (USDA/NIFA)  USDA-NIFA-SCRI-010311	The purpose of the SCRI program is to address the critical needs of the specialty crop industry by awarding grants to support research and extension that address key challenges of national, regional, and multi-state importance in sustaining all components of food and agriculture, including conventional and organic food production systems. Projects must address at least one of the five focus areas. <a href="https://www.nifa.usda.gov/grants/funding-opportunities/specialty-crop-research-initiative">https://www.nifa.usda.gov/grants/funding-opportunities/specialty-crop-research-initiative</a>	Up to \$2 million, for up to 5 years	Proposal: 12/8/23
		<b>BIOENGINEERING (3)</b>		
4.	NSF/CASIS Collaboration on Tissue Engineering and Mechanobiology on the International Space Station (ISS) to Benefit Life on Earth (NSF/CASIS)  NSF 24-502	This NOFO seeks proposals that make use of the ISS National Lab for flight research projects in the field of biomedical engineering. Responsive proposals will describe how they will utilize the ISS National Lab to develop novel ideas into discovery-level and transformative projects that integrate engineering and life sciences. <a href="https://www.nsf.gov/pubs/2024/nsf24502/nsf24502.htm">https://www.nsf.gov/pubs/2024/nsf24502/nsf24502.htm</a>	Up to \$1.6 million	Feasibility letter: 1/15/24 Proposal: 3/15/24
5.	NSF/CASIS Collaboration on Transport Phenomena Research on the International Space Station (ISS) to Benefit Life on Earth (NSF/CASIS)  NSF 24-501	This solicitation seeks proposals that make use of the ISS National Lab for research projects in the fields related to the Transport Phenomena Cluster and Nanoscale Interactions programs. Responsive proposals will describe using the ISS National Lab for development and testing of fluid dynamics, particulate and multiphase processes, combustion and fire systems, thermal transport processes, and nanoscale interactions. <a href="https://www.nsf.gov/pubs/2024/nsf24501/nsf24501.htm">https://www.nsf.gov/pubs/2024/nsf24501/nsf24501.htm</a>	Dependent upon proposal and available funds, for up to 4 years	Feasibility letter: 1/10/24 Proposal: 3/4/24
6.	Presolicitation: ARPA-H Resilient Extended Automatic Cell Therapies (REACT) (ARPA-H)  ARPA-H-MAI-24-01-02	REACT aims to overcome the problems surrounding medication non-adherence by creating two different—but related—bioelectronic devices capable of treating chronic conditions remotely. These devices will be implanted in patients during minor outpatient surgery and will interface with a simple software platform or app that allows users to track their condition directly. Proposers' Day is 11/16/23. The BAA is forthcoming. <a href="https://sam.gov/opp/db6c55d294ed42b29771e964a43ff6b7/view">https://sam.gov/opp/db6c55d294ed42b29771e964a43ff6b7/view</a>	Dependent upon proposal and award mechanism	Estimated abstract date: 11/30/23
		<b>CANCER (12)</b>		
7.	Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 CT Optional) (NIH/NCI)  PAR-23-308	The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity populations and underrepresented students and Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education, and outreach. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-308.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-308.html</a>	Up to \$2.2 million per year, for up to 5 years Dependent upon proposal and partners	Letter of intent: 12/16/23 Proposal: 1/16/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
8.	Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) (NIH/NCI)  PAR-24-039	This NOFO is a continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible New Investigators and Early Stage Investigators from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-039.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-039.html</a>	Up to \$275,000, for up to 2 years	Proposal: 6/18/24
9.	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) (NIH/NCI)  PAR-23-313 (UH2/UH3) PAR-23-314 (UH3)	These NOFOs invite applications to accelerate the adoption and support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. They will also support the validation of pharmacodynamic markers and markers of toxicity.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-313.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-313.html</a> (UH2/UH3) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-314.html">https://grants.nih.gov/grants/guide/pa-files/PAR-23-314.html</a> (UH3)	Up to \$275,000, for up to 2 years (UH2) Up to \$250,000 per year, for up to 3 years (UH3)	Proposal: 2/20/24
10.	NOSI: NCI Entrepreneurial Education Programs to Facilitate Commercialization of Cancer Relevant Technologies (NIH/NCI)  NOT-CA-24-001	This NOSI serves to encourage applications for entrepreneurial education programs that are aimed at developing the skillset of graduate students and postdoctoral researchers, as well as early-career scientists, in fields relevant to the NCI mission. The overarching objective of this NOSI is to expand the skillset of the upcoming generation of research trainees and facilitate the commercialization of cancer relevant technologies.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-001.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-001.html</a>	Up to \$300,000 per year, for up to 5 years	Multiple deadlines; NOSI open through 1/8/27
11.	RFI: Facilitate Cancer Systems immunology Research (NIH/NCI)  NOT-CA-24-003	This RFI aims to identify the challenges faced by cancer systems immunologists to not only characterize tumor-immune ecosystems, but also determine their mechanistic and functional significance, thus enabling the rational design of next generation immunoprevention and immunotherapies and their combinations.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-003.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-003.html</a>	N/A	Response: 2/29/24
12.	Pre-Announcement: Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) (NIH/NCI)  NOT-CA-23-096	This NOFO will support research projects that propose early phase investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the NCI's Division of Cancer Treatment and Diagnosis (DCTD), and the Office of HIV and AIDS Malignancies.  <a href="https://www.grants.gov/search-results-detail/350667">https://www.grants.gov/search-results-detail/350667</a>	TBD	Estimated post date: 1/2/24 Estimated proposal date: 2/5/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>CANCER</b>		
13.	NOSI: Research Projects to Develop Oncoaging Models for Cancer Research (NIH/NCI/NIA)  NOT-CA-23-092	This notice intends to foster novel collaborations among researchers in aging biology, cancer biology, and cancer experimental therapeutics to incorporate age-related biological features into in vitro and/or in vivo models where the cancer of interest shows growth and/or metastasis.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-092.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-092.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/31/27
		<b>CANNABIS RESEARCH (1)</b>		
14.	Resource Center for Cannabis and Cannabinoid Research (U24 Clinical Trial Not Allowed) (NIH)  RFA-AT-24-006	The Center is expected to be a focal point for researchers entering the cannabis research space and to support the development and establishment of research tools and studies that will improve upon and eventually change the landscape of cannabis research.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-24-006.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-24-006.html</a>	Up to \$850,000 per year, for up to 5 years	Letter of intent: 3/16/24 Proposal: 4/16/24
		<b>CARDIOVASCULAR AND PULMONARY HEALTH (4)</b>		
15.	NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) (NIH/NHLBI)  PAR-24-049	The purpose of this NOFO is to support research that will address the critical gaps in information needed to complete the protocol or other required study documents to plan for a future Phase II-IV trial.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-049.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-049.html</a>	Up to \$450,000, for up to 3 years	Letter of intent: 1/16/24 Proposal: 2/16/24
16.	NOSI: Pulmonary Complications of Hematopoietic Stem Cell Transplantation (HCT) (NIH/NHLBI)  NOT-HL-23-116	To continue to address this wide array of outstanding scientific questions involving post-HCT pulmonary complications across the lifespan, the NHLBI is interested in renewing its support for observational, mechanistic, and discovery-based research studies, mechanistic clinical trials, and novel medical device development that aim to elucidate mechanisms of acute airway, alveolar and vascular injury after HCT, and explore mechanism-based therapeutic strategies in this challenging field.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-116.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-116.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/27
		<b>CHRONIC PAIN &amp; PAIN MANAGEMENT (1)</b>		
17.	HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) (NIH)  RFA-NS-24-019	This NOFO supports preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. Applicants must have a promising biologic or small molecule starting point for optimization, robust biological rationale for the intended approach, and identified assays for optimization of the agent.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-019.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-019.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 12/24/23 Proposal: 1/24/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>COGNITIVE AND BRAIN HEALTH (5)</b>		
18.	Cognitive Neuroscience (CogNeuro) (NSF)  PD 24-1699	The Cognitive Neuroscience (CogNeuro) Program seeks to fund proposals that can advance our understanding of the neural mechanisms underlying human cognition and behavior. Funded proposals typically advance theories in cognitive neuroscience by relating precise and rich quantifications of physiology, cognition and behavior with each other. <a href="https://new.nsf.gov/funding/opportunities/cognitive-neuroscience-cogneuro-0">https://new.nsf.gov/funding/opportunities/cognitive-neuroscience-cogneuro-0</a>	Dependent upon proposal and available funding	Submission window: 1/15-2/1/24
19.	BRAIN Initiative Connectivity across Scales Data Coordinating Center (BRAIN CONNECTS DCC) (U24 Clinical Trial Not Allowed) (NIH)  RFA-NS-24-028	Through this NOFO, NIH expects to fund one or more BRAIN CONNECTS DCCs, which will collaborate with the technology development projects to (1) coordinate activities of the BRAIN CONNECTS Network, (2) develop and harmonize common data processing pipelines, (3) integrate and disseminate data analytic tools and capabilities, (4) establish a unified knowledge base for connectivity data of diverse modalities, and (5) organize and implement outreach and engagement to the wider research community and the general public. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-028.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-028.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 12/29/23 Proposal: 1/29/24
20.	Pre-Announcement: Translational Neural Devices (R61/R33 - Clinical Trial Optional) (NIH/NINDS)  NOT-NS-24-021	NINDS intends to solicit applications for research pursuing translational activities and small clinical studies to advance the development of low risk therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-021.html">https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-021.html</a>	TBD	Estimated post date: 2/22/24 Estimated proposal date: 5/28/24
21.	Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required) (NIH/NINDS/NIA)  RFA-NS-24-013	This RFA is soliciting applications proposing placebo-controlled, phase 3 clinical trials to determine the efficacy and safety of FDA approved monoclonal antibody therapies directed against amyloid compared to placebo in diverse "mixed dementia" populations with a focus on vascular contributions to cognitive impairment and dementia (VCID). <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-013.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-013.html</a>	Up to \$6.7 million per year, for up to 7 years	Letter of intent: 1/20/24 Proposal: 2/20/24
22.	Microphysiological Systems to Advance Precision Medicine for AD/ADRD Treatment and Prevention (U54 Clinical Trial Not Allowed) (NIH/NIA)	The overarching objective of this initiative is to create AD/ADRD MPS Translational Centers focused on establishing an infrastructure to develop standardized and deeply phenotyped 2D and 3D MPS models, establishing the translational validity of these MPS models to recapitulate the molecular and network perturbations identified in AD/ADRD, and ensuring rapid and broad distribution of the MPS models, data, and analytical methods for use in basic research and therapy development.	Up to \$2.5 million per year, for up to 5 years	Letter of intent: 1/15/24 Proposal: 2/15/24



	RFA-AG-24-040	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-040.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-040.html</a>		
	<b>Title (Agency) and Opportunity #</b>	<b>Description and Link</b>	<b>Funding Level</b>	<b>Deadline</b>
		<b>COMBAT CASUALTY CARE (1)</b>		
23.	Demonstration and Prize Competition for the Passive Data Collection using Autonomous Documentation (AutoDoc) Project (MTEC)  MTEC-E24-02-AutoDocPrize	This RPP is focused on identifying a system of sensor suites that can reliably and passively collect the core data needed to identify casualty status, key tasks performed by medics, and real-time resource use in casualty care scenarios under realistic battlefield conditions. This demonstration and prize competition focuses on the use of mature sensor technologies to support passive data collection for autonomous tactical combat casualty care (TCCC).  <a href="https://mtec-sc.org/wp-content/uploads/2023/10/MTEC-E24-02-AutoDocPrize.pdf">https://mtec-sc.org/wp-content/uploads/2023/10/MTEC-E24-02-AutoDocPrize.pdf</a>	Up to \$37,500	Proposal: 11/20/23
		<b>COMMUNICATION DISORDERS (3)</b>		
24.	Advancing Hearing and Balance Research Using Auditory and Vestibular Organoids (R21/R01 Clinical Trial Not Allowed) (NIH/NIDCD)  PAS-24-057 (R21) PAS-24-058 (R01)	These NOFOs encourage innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAS-24-057.html">https://grants.nih.gov/grants/guide/pa-files/PAS-24-057.html</a> (R21) <a href="https://grants.nih.gov/grants/guide/pa-files/PAS-24-058.html">https://grants.nih.gov/grants/guide/pa-files/PAS-24-058.html</a> (R01)	Up to \$275,000, for up to 2 years (R21) Up to \$499,999 per year, for up to 5 years (R01)	Proposal: 2/16/24 (R21) Proposal: 2/5/24 (R01)
25.	NIDCD Cooperative Agreement for and Low Risk Clinical Trials in Communication Disorders (U01/R01 - Clinical Trial Required) (NIH/NIDCD)  PAR-24-050 (U01) PAR-24-051 (R01)	The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-050.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-050.html</a> (U01) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-051.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-051.html</a> (R01)	Dependent upon proposal, for up to 5 years (U01) Up to \$500,000 per year, for up to 5 years (R01)	Letter of intent: 1/27/24 Proposal: 2/27/24 (U01) Letter of intent: 1/5/24 Proposal: 2/5/24 (R01)
		<b>DENTAL AND CRANIOFACIAL RESEARCH (4)</b>		
26.	RPI: Military Dental Research – Seeking New Technologies and Development Partners (MTEC)  MTEC-24-03-Dental_RPI	There is a pressing need for novel biomedical, engineering, and clinical devices and products that can effectively address the multifaceted consequences of delayed care, care in challenging environments, and combat injuries, while prioritizing long-term comprehensive care, to restore both physical and cosmetic aspects of the face and maxillofacial region.  <a href="https://mtec-sc.org/wp-content/uploads/2023/10/24-03-Dental_RPI.pdf">https://mtec-sc.org/wp-content/uploads/2023/10/24-03-Dental_RPI.pdf</a>	N/A	Information paper: 11/30/23
27.	NOSI: Chronic Inflammation of the Oral Cavity - An Agent for Oral Mucosal Disease (NIH/NIDCR)	The purpose of this NOSI is to encourage research studies that investigate the mechanisms of chronic inflammation of the oral cavity, including chronic oral manifestations of systemic diseases.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DE-23-007.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DE-23-007.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/10/27





	NOT-DE-23-007			
	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DOWN SYNDROME (3)</b>		
28.	<p>Cohort Research Sites (DS-CRS), Clinical Cohort Coordinating Center (DS-4C), Federated Biobanking resource for the Down Syndrome Cohort Study Program (DS-CDP) across the lifespan for the INCLUDE Project (NIH)</p> <p>RFA-OD-24-003 (U01) RFA-OD-24-004 (U24) RFA-OD-24-005 (U54)</p>	<p>The DS-CDP will be a cooperative program committed to the assembly of a diverse cohort of people with Down syndrome (DS). The DS-CRS will serve to identify and enroll people with Down syndrome into a common diverse cohort. DS-CRS will work cooperatively with a Down Syndrome Clinical Cohort Coordinating Center (DS-4C) that will be responsible for overall management and oversight for the DS-CDP and assuring DS-CRS data is incorporated into the INCLUDE data repository maintained by the INCLUDE Data Coordinating Center (DCC). A related NOFO (NOT-OD-23-136) will support a federated biobanking system for the INCLUDE Project.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-24-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-24-003.html</a> (U01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-24-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-24-004.html</a> (U24) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-24-005.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-24-005.html</a> (U54)</p>	<p>Up to \$300,000 per partner site per year, for up to 5 years (U01) Up to \$3.75 million per year, for up to 5 years (U24) Dependent upon proposal, for up to 5 years (U54)</p>	<p>Letter of intent: 11/15/23 Proposal: 12/15/23 (U01/U24) Letter of intent: 12/26/23 Proposal: 1/26/24 (U54)</p>
		<b>ENDOCRINE AND METABOLIC DISEASES (3)</b>		
29.	<p>Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed) (NIH/NIDDK/NIAID)</p> <p>RFA-DK-23-004</p>	<p>This NOFO welcomes applications for the Consortium on Modeling Autoimmune Diabetes (CMAD) that supports the development of in vitro and in vivo models of type 1 diabetes (T1D) to enable studies of human T1D pathophysiology and to serve as platforms for preclinical assessments of new T1D interventions.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-004.html</a></p>	<p>Up to \$750,000 per year, for up to 5 years</p>	<p>Proposal: 3/20/24</p>
30.	<p>Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional) (NIH/NIDDK)</p> <p>RFA-DK-25-003</p>	<p>DDRCCs are meant to improve communication among investigators and to integrate, coordinate, and foster interdisciplinary research involving the etiology, treatment, and prevention of digestive and/or liver diseases.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-003.html</a></p>	<p>Up to \$750,000 per year, for up to 5 years</p>	<p>Letter of intent: 1/22/24 Proposal: 2/22/24</p>
31.	<p>Pre-Announcement: Cardiovascular Repository – Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed) (NIH/NIDDK/NHLBI)</p> <p>NOT-DK-24-001</p>	<p>CaRe-T1D will be the source of well-characterized and preserved human cardiovascular tissue for the consortium. This resource will enable ground-breaking research on human tissue from donors with T1D, T2D, and without diabetes. CaRe-T1D will also serve as the CC and bioinformatics core of the consortium.</p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-001.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-001.html</a></p>	<p>TBD</p>	<p>Estimated post date: 12/11/23 Estimated proposal date: 4/11/24</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>GENOMICS (6)</b>		
32.	<p>Advancing Genomic Medicine Research (R01/R21 Clinical Trial Optional/R03 CT Not Allowed) (NIH/NHGRI/NCI)</p> <p>RFA-HG-23-032 (R01) RFA-HG-23-033 (R21) RFA-HG-23-048 (R03)</p>	<p>These NOFOs invite proposals that stimulate innovation and advance understanding of when, where, and how best to implement the use and sharing of genomic information and technologies in clinical care provided to all persons irrespective of racial/ethnic background or socioeconomic status. Applications should focus on genomic medicine and the health outcomes and policy implications of that clinical use.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-032.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-032.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-033.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-033.html</a> (R21) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-048.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-048.html</a> (R03)</p>	<p>Up to \$500,000 per year, for up to 5 years (R01) Up to \$250,000 per year, for up to 3 years (R21) Up to \$50,000 per year, for up to 2 years (R03)</p>	<p>Proposal: 12/1/23</p>
33.	<p>NOSI: Advancing Genomic Medicine Research through Small Businesses (NIH/NHGRI)</p> <p>NOT-HG-24-002</p>	<p>NHGRI seeks applications to research and develop innovative solutions with commercial potential, such as new clinical services, computer software, mobile apps, and other products, that enable the use of genomic information in clinical care for individuals of all racial/ethnic backgrounds and socioeconomic statuses.</p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-002.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-002.html</a></p>	<p>Up to \$295,924 (Phase I)</p>	<p>Multiple deadlines; NOSI open through 9/6/26</p>
34.	<p>IND-enabling Studies for Platform Clinical Trials of Genome Editing in Multiple Diseases (U01 Clinical Trial Not Allowed) (NIH Common Fund)</p> <p>RFA-RM-24-001</p>	<p>The purpose of this NOFO is to provide support for applications for IND-enabling studies for the development of a novel in vivo genome editing therapeutic platform (genome editor plus delivery system) for two or more disease indications, using the same genome editor, route of administration, and delivery system.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-001.html</a></p>	<p>Up to \$2 million per year for FY24-25 Up to \$3 million per year for FY26-27</p>	<p>Letter of intent: 1/22/24 Proposal: 2/22/24</p>
		<b>HEALTH IT &amp; DATA (6)</b>		
35.	<p>PREPARE Challenge: Pioneering Research for Early Prediction of Alzheimer's Disease &amp; Related Dementias (NIH/NIA)</p>	<p>The overarching goal of this Challenge is to spur and reward the development of solutions for accurate, innovative, and representative early prediction of AD/ADRD. Phase I: Find IT! The first phase will focus on identifying, accessing and/or building representative, inclusive, open, shareable datasets that can be used for early prediction of AD/ADRD with an emphasis on addressing biases in existing data sources.</p> <p><a href="https://www.challenge.gov/?challenge=prepare-challenge">https://www.challenge.gov/?challenge=prepare-challenge</a></p>	<p>Total prizes of \$650,000</p>	<p>Executive summary: 1/17/24 Proposal: 1/31/24</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HEALTH IT &amp; DATA</b>		
36.	NIDDK Central Repository Data-Centric Challenge: Enhancing NIDDK datasets for future Artificial Intelligence (AI) applications. (NIH/NIDDK)	NIDDK is seeking innovative approaches to enhance the utility of NIDDK datasets for AI applications. Towards this, the goals of the NIDDK-CR Data Centric Challenge will be to 1) generate an “AI-ready” dataset that can be used for future data challenges, and 2) to produce methods that can be used to enhance the AI-readiness of NIDDK data. <a href="https://www.challenge.gov/?challenge=niddk-central-repository-data-centric-challenge">https://www.challenge.gov/?challenge=niddk-central-repository-data-centric-challenge</a>	N/A	Proposal: 11/30/23
37.	AI Tech Sprint for Documenting VA Clinical Encounters and Integrating Community Care Data (VA)	This Tech Sprint is an opportunity to pioneer innovations that will elevate healthcare data management and clinical practice for the VA system. The mission is to enhance the quality of healthcare for our veterans, tackling specific challenges that, if solved, can make a tangible impact on their lives. There are two tracks: Ambient Dictation for Clinical Encounter Notes and Community Care Document Processing (CCDP). <a href="https://www.challenge.gov/?challenge=ai-tech-sprint-for-documenting-va-clinical-encounters-and-integrating-community-care-data">https://www.challenge.gov/?challenge=ai-tech-sprint-for-documenting-va-clinical-encounters-and-integrating-community-care-data</a>	Total prizes of \$1 million	Proposal: 1/5/24
38.	AHRQ Challenge: Designing the Optimal Future State of CDS Connect (AHRQ)	The rapid evolution and growing role of digital technologies in healthcare has increased the importance of CDS Connect as a freely available source of up-to-date tools and resources. To ensure that CDS Connect is sustainable and will continue to evolve to meet the needs of its stakeholders, AHRQ is exploring collaborative initiatives with private industry and non-profit entities as a potential path forward. AHRQ is announcing a competition to solicit innovative input on the future functionalities and roles of CDS Connect through a collaborative initiative with the Agency. <a href="https://www.challenge.gov/?challenge=ahrq-challenge-designing-the-optimal-future-state-of-cds-connect">https://www.challenge.gov/?challenge=ahrq-challenge-designing-the-optimal-future-state-of-cds-connect</a>	Total prizes of \$100,000	Proposal: 11/22/23
39.	ARPA-H Biomedical Data Fabric (BDF) Toolbox (ARPA-H)  ARPA-H-MAI-24-01-01	The ARPA-H BDF Toolbox project will create the software foundations that make it far easier and faster to integrate these disparate data sources in a meaningful way and make the data available to a broad set of R&D end users to accelerate the development of novel health technologies to improve health outcomes for all Americans. <a href="https://sam.gov/opp/d4d90aff105c4ffebe264a47642deef3/view">https://sam.gov/opp/d4d90aff105c4ffebe264a47642deef3/view</a>	Up to \$10 million, for up to 2 years Dependent upon award mechanism	Proposal: 11/28/23
40.	NOSI: Applications of Data Science in Translational Dental, Oral, and Craniofacial Research (NIH/NIDCR) NOT-DE-24-003	The initiative will promote research, research training, and career development projects that develop and use state of the art data science resources, methods, and tools in biomedical and behavioral DOC research spanning the full translational continuum from basic to clinical. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DE-24-003.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DE-24-003.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HIV/AIDS (10)</b>		
41.	HIV Vaccine Research and Design (HIVRAD) Program (Po1 CT Not Allowed) (NIH/NIAID)  PAR-24-037	This NOFO supports multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html</a>	Up to \$2.5 million per year, for up to 5 years	Letter of intent: 2/13/24 Proposal: 3/13/24
42.	Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 CT Not Allowed) (NIH/NIDA)  RFA-DA-25-011	This NOFO supports high risk high impact studies that 1) develop or apply novel tools or technologies or 2) test novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html</a>	Up to \$700,000 per year, for up to 5 years	Letter of intent: 7/14/24 Proposal: 8/14/24
43.	Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (U19 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-23-057	This NOFO supports research to better understand the impact of host and viral heterogeneity on pathogenesis of disease, viral persistence, and immunopathology of Hepatitis B (HBV) and inform cure strategies for HBV in people living with HIV (PLWH).  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-057.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-057.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 2/3/24 Proposal: 3/13/24
44.	Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 CT Optional) (NIH/NIDA)  RFA-DA-25-022	The purpose of this NOFO is to support milestone-driven preclinical research that will advance the development of new technology or tools to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD therapeutic and mechanistic research.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-022.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-022.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 10/15/24 Proposal: 11/15/24
45.	Engineering and Preclinical Development of Biological Products that Eliminate HIV-infected Cells (UG3/UH3 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-23-060	This NOFO supports the late-stage engineering and preclinical development of innovative biological products that safely and specifically kill HIV-infected cells. Products of interest include but are not limited to broadly neutralizing antibodies (bNAbs), their derivatives, and other soluble, antibody-like molecules.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-060.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-060.html</a>	Up to \$500,000 per year, for up to 3 years (UG3) Up to \$750,000 per year, for up to 4 years (UH3)	Letter of intent: 2/13/24 Proposal: 3/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>HIV/AIDS</b>		
46.	Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed) (NIH/NIAID/NICHD/NIMH)  RFA-AI-23-061	This NOFO aims to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-061.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-061.html</a>	Up to \$850,000 per year, for up to 2 years (R61) Up to \$1.25 million per year, for up to 3 years (R33)	Letter of intent: 2/13/24 Proposal: 3/13/24
47.	Applying Imaging Pipelines for Spatial Characterization of Cellular Interactions in HIV-related CNS Pathology and/or Substance Use (R61/R33 Clinical Trial Not Allowed) (NIH/NIDA)  RFA-DA-24-030	This NOFO aims to support the development and application of innovative ex-vivo imaging technologies, along with necessary coordinated pipelines encompassing tissue procurement, histological processing and computation to enable spatial analysis and in situ molecular annotation of cell populations involved in central nervous system (CNS) HIV infection, persistence, and neuropathogenesis.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-030.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-030.html</a>	Up to \$300,000 per year, for up to 3 years (R61) Up to \$400,000 per year, for up to 2 years (R33)	Letter of intent: 1/8/24 Proposal: 2/8/24
48.	Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional) (NIH/NIDA)  RFA-DA-25-021	This NOFO aims to solicit applications for research targeted at elucidating the effect of HIV and/or anti-retroviral therapy on the growth, development and functioning of the placenta in pregnant individuals with substance use/misuse, the impact of placental abnormalities on maternal outcomes, and the underlying mechanisms.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-021.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-021.html</a>	Dependent upon proposal, for up to 5 years	Letter of intent: 10/15/24 Proposal: 11/15/24
49.	Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 CT Optional) (NIH/NCI)  RFA-CA-24-006	NCI intends to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes, or ameliorate the severity of disease.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-006.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-006.html</a>	Up to \$750,000 per year, for up to 5 years	Letter of intent: 11/21/23 Proposal: 12/21/23
50.	Targeting Inflammasomes in HIV and Substance Use (R01/R21 Clinical Trial Not Allowed) (NIH/NIDA)  RFA-DA-25-012 (R01) RFA-DA-25-013 (R21)	These NOFOs encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs).  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-012.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-012.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-013.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-013.html</a> (R21)	Up to \$500,000 per year, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 2/13/24 Proposal: 3/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>IMMUNOLOGY &amp; INFECTIOUS DISEASE (7)</b>		
51.	Pre-Announcement: Antigens Predicted for Broad Viral Efficacy through Computational Experimentation (APECx) (ARPA-H)  75N99224R00001	The APECx program aims to create a toolkit to enable accurate chimeric and broadly efficacious vaccine Ag discovery through predictive modeling, high-throughput functional experimentation, and protein engineering. To fundamentally transform the vaccine research and development (R&D) sector, APECx will develop an innovative viral Ag prediction pipeline for broad efficacy by combining expedited experimental protein structure and function determination with highthroughput Ag screening.  <a href="https://sam.gov/opp/7e88512607e64898a6c2826db8f13a87/view">https://sam.gov/opp/7e88512607e64898a6c2826db8f13a87/view</a>	Dependent upon proposal and award mechanism	Proposer's Day: 11/17/23
52.	Pre-Announcement: Center of Excellence for Systems Modeling of Infection and Immunity across Biological Scales (U54 Clinical Trial Not Allowed) (NIH/NIAID)  NOT-AI-23-073	The primary focus of the CoE will be modeling research that spans NIAID-funded work and includes data from basic science, clinical trials and studies, and epidemiologic research. Generation of new data will be limited to only what is needed for model testing and validation. The CoE will include a broad range of biomedical and subject matter expertise that includes computational modeling, systems modeling, mechanistic modeling, informatics, and coordinating center experience.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-073.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-073.html</a>	Up to \$5 million	Estimated post date: 12/28/23 Estimated proposal date: 6/5/24
53.	NOSI: Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives (NIH/NIAID)  NOT-AI-23-076	The purpose of this NOSI is to invite applications for research on the use of targeted protein and nonprotein degradation (e.g., RNA) as it relates to the development of anti-infective strategies against viral, bacterial, parasitic, and fungal pathogens and/or their toxins.  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-076.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-076.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/17/26
		<b>MATERNAL AND PEDIATRIC HEALTH (3)</b>		
54.	Pre-Announcement: Maternal Morbidity and Mortality Topical PCORI Funding Announcement – Cycle 1 2024 (PCORI)	This PFA seeks to fund high-quality, patient-centered comparative clinical effectiveness research (CER) projects that focus on maternal morbidity and mortality (MMM). Primary outcomes of interest may include MMM; SMM; condition-specific outcomes; healthcare utilization, including readmission and emergency department visits; labor characteristics.  <a href="https://www.pcori.org/funding-opportunities/announcement/maternal-morbidity-and-mortality-topical-pcori-funding-announcement-cycle-1-2024">https://www.pcori.org/funding-opportunities/announcement/maternal-morbidity-and-mortality-topical-pcori-funding-announcement-cycle-1-2024</a>	Up to \$12 million, for up to 5 years	System opens: 1/9/24 Letter of intent: 2/6/24 Proposal: 5/7/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>MATERNAL AND PEDIATRIC HEALTH</b>		
55.	Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - CT Optional) (NIH)  PAR-24-059	This NOFO supports multidisciplinary and innovative intervention research to understand and address maternal morbidity and mortality in the United States, particularly but not exclusively among racial and ethnic minority, socioeconomically disadvantaged, and underserved rural populations, with a focus on understudied healthcare factors.  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-059.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-059.html</a>	Dependent upon proposal, for up to 5 years	Proposal: 2/5/24
		<b>MEDICAL COUNTERMEASURES (3)</b>		
56.	Gene-Encoded MCM Development and Response Platform (MCDC)	The goal of this project is to mature and implement a rapid response MCM capability for prophylaxis (and potentially treatment) for biological, toxin, and/or chemical threats using in vivo delivered nucleic acid (DNA or RNA) to express monoclonal antibodies at protective/therapeutic serum concentrations in operationally relevant timeframes.  <a href="https://www.medcbrn.org/solicitations/">https://www.medcbrn.org/solicitations/</a>	TBD	Proposal: 12/4/23
57.	Development of Candidate Radiation/Nuclear Medical Countermeasures (MCMs) (U01 Clinical Trial Not Allowed) (NIH/NIAID)  RFA-AI-23-059	This NOFO supports investigator-initiated research at all stages of development that is specifically focused on the development of medical countermeasures (MCMs) to mitigate/treat injuries arising from radiation exposure during a public health emergency.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-059.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-059.html</a>	Up to \$350,000 per year, for up to 5 years	Letter of intent: 12/26/23 Proposal: 1/26/24
58.	Pre-Announcement: Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed) (NIH/NIAID)  NOT-AI-23-071	This cooperative agreement program will support multidisciplinary translational research Centers focused on generating, validating, and advancing medical countermeasures against bacteria and/or fungi that have known and emerging resistance to current therapies.  <a href="https://www.grants.gov/search-results-detail/350664">https://www.grants.gov/search-results-detail/350664</a>	TBD	Estimated post date: 12/29/23 Estimated proposal date: 4/29/24
		<b>MENTAL HEALTH (3)</b>		
59.	Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R01/R21 CT Optional) (NIH/NIMH)  RFA-MH-24-180 (R01) RFA-MH-24-181 (R21)	These NOFOs encourage applications that focus on understanding bidirectional relationships between social media use and adolescent mental illness, psychiatric symptoms, and risk or resilience for psychopathology.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-180.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-180.html</a> (R01) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-181.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-181.html</a> (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R33)	Letter of intent: 2/1/24 Proposal: 3/1/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>MENTAL HEALTH</b>		
60.	NOSI: Adopting Techniques and Tools Developed from the BRAIN Initiative Toward NIMH Strategic Research Priorities (NIH/NIMH)  NOT-MH-24-290	The goal of this NOSI is to express NIMH's interest in leveraging these developments to understand nervous system function in the service of cognition, social, or affective processing. NIMH encourages the use of network- or cell-type-specific manipulations to causally probe circuit function. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-290.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-290.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/10/27
		<b>MILITARY PROTOTYPE ADVANCEMENT INITIATIVE (1)</b>		
61.	Military Prototype Advancement Initiative (MPAI) (MTEC)  MTEC-24-01-MPAI	This RPP solicits a broad range of medical prototype technological and knowledge solutions related to the Focus Areas of Interest listed below. Proposed solutions may include medical techniques, knowledge products, and materiel. The focus areas are: Combat Casualty Care, Military Infectious Diseases, Military Operational Medicine, and USAF School of Aerospace Medicine. Topics include Precision Medicine, Carcinogens, Wound Management/Burn Healing, Vaccines, and Infection Prevention. <a href="https://mtec-sc.org/wp-content/uploads/2023/10/MTEC-24-01-MPAI-RPP.pdf">https://mtec-sc.org/wp-content/uploads/2023/10/MTEC-24-01-MPAI-RPP.pdf</a>	Dependent upon proposal	Proposal: 1/15/24
		<b>MUSCULOSKELETAL HEALTH (2)</b>		
62.	Exploratory Clinical Trial Grants and Clinical Observational (CO) Studies in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required/R01 Clinical Trial Not Allowed) (NIH/NIAMS)  PAR-24-035 (R61) PAR-24-036 (R01)	These NOFOs support exploratory clinical trials that can be completed within a limited time frame; and clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html</a> (R61) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-036.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-036.html</a> (R01)	Up to \$600,000, for up to 3 years (R61) Up to \$475,000, for up to 4 years (R01)	Proposal: 3/4/24
		<b>PALLIATIVE CARE (4)</b>		
63.	Pre-Announcement: Consortium for Palliative Care Research Across the Lifespan (U54 Clinical Trial Required) (NIH)  NOT-AG-23-050	The aim of the Consortium will be to provide resources, expertise, and coordination to advance innovative, high-quality research on palliative care for those living with serious illnesses across the lifespan. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-050.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-050.html</a>	Up to \$9.5 million for FY25, up to \$14 million per year for FY26-FY29	Estimated post date: 12/14/23 Estimated proposal date: 2/14/24





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>PALLIATIVE CARE</b>		
64.	NOSI: Palliative Care in the Care Continuum among Persons with Serious Heart, Lung, Blood and Sleep (HLBS) Diseases and their Caregivers (NIH)  NOT-HL-23-117	The goal of this NOSI is to support research focused on palliative care for patients with serious HLBS diseases, and specifically encourage integrating palliative care early in the continuum of care; research on strategies to educate physicians on the role of palliative care; addressing care transitions to/from palliative care settings and coordination of care; research on symptom management; and addressing palliative care needs of populations experiencing health disparities. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-117.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-117.html</a>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/27
		<b>PATIENT-CENTERED RESEARCH (7)</b>		
65.	Pre-Announcement: Advancing the Science of Engagement PCORI Funding Announcement – Cycle 1 2024 (PCORI)	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research. <a href="https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-pcori-funding-announcement-cycle-1-2024">https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-pcori-funding-announcement-cycle-1-2024</a>	Up to \$1.5 million, for up to 3 years	System opens: 1/9/24 Letter of intent: 2/6/24 Proposal: 5/7/24
66.	Pre-Announcement: Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research – 2024 Standing PFA (Cycle 1 2024) (PCORI)	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER. <a href="https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-2024-standing-pfa-cycle-1-2024">https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-2024-standing-pfa-cycle-1-2024</a>	Up to \$750,000, for up to 3 years	System opens: 1/9/24 Letter of intent: 2/6/24 Proposal: 5/7/24
67.	Pre-Announcement: Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments – Cycle 1 2024 (PCORI)	For this PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). <a href="https://www.pcori.org/funding-opportunities/announcement/open-competition-pcori-funding-announcement-implementation-findings-pcoris-research-investments-cycle-1-2024">https://www.pcori.org/funding-opportunities/announcement/open-competition-pcori-funding-announcement-implementation-findings-pcoris-research-investments-cycle-1-2024</a>	Up to \$2.5 million, for up to 4 years	System opens: 1/9/24 Letter of intent: 2/6/24 Proposal: 5/7/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>PATIENT-CENTERED RESEARCH</b>		
68.	Pre-Announcement: Implementation of Effective Shared Decision Making Approaches in Practice Settings -- Cycle 1 2024 (PCORI)	This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision making strategies that address existing barriers and obstacles to uptake and maintenance, so that these interventions are effectively and sustainably integrated into practice. The SDM strategy must have demonstrated effectiveness on patient, caregiver, or healthcare provider decision making using widely accepted metrics; the corresponding implementation approach must have potential for use and scalability beyond the targeted implementation setting. <a href="https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-cycle-1-2024">https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-cycle-1-2024</a>	Up to \$2.5 million, for up to 4 years	System opens: 1/9/24 Letter of intent: 2/6/24 Proposal: 5/7/24
69.	Pre-Announcement: Phased Large Awards for Comparative Effectiveness Research (PLACER) -- Cycle 1 2024 (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. Applications must address at least one of the National Priorities for Health. <a href="https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-placer-cycle-1-2024">https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-placer-cycle-1-2024</a>	Up to \$22 million, for up to 6.5 years	System opens: 1/9/24 Letter of intent: 2/6/24 Proposal: 5/7/24
70.	Pre-Announcement: Broad Pragmatic Studies Funding Announcement -- 2024 Standing PFA (Cycle 1 2024) (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of <a href="#">twelve topic themes</a> , based on how their proposed research aligns with the themes. <a href="https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2024-standing-pfa-cycle-1-2024">https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2024-standing-pfa-cycle-1-2024</a>	Up to \$12 million, for up to 5 years Dependent upon award mechanism	System opens: 1/9/24 Letter of intent: 2/6/24 Proposal: 5/7/24
71.	Pre-Announcement: Intellectual and Developmental Disabilities Topical PCORI Funding Announcement -- Cycle 1 2024 (PCORI)	This PFA seeks to fund high-quality, patient-centered comparative clinical effectiveness research (CER) projects that focus on people with intellectual and developmental disabilities (IDD). Three Special Areas of Emphasis are: Promoting Sleep Health, Improving Health and Quality of Life in Down Syndrome, Improving Care Delivery. <a href="https://www.pcori.org/funding-opportunities/announcement/intellectual-and-developmental-disabilities-topical-pcori-funding-announcement-cycle-1-2024">https://www.pcori.org/funding-opportunities/announcement/intellectual-and-developmental-disabilities-topical-pcori-funding-announcement-cycle-1-2024</a>	Up to \$12 million, for up to 5 years	System opens: 1/9/24 Letter of intent: 2/6/24 Proposal: 5/7/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>REPRODUCTIVE HEALTH (1)</b>		
72.	Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed) (NIH/NICHD)  RFA-HD-25-008	This NOFO intends to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization using high molecular weight polymers, biologics, and devices. This NOFO aims to position innovative and validated methods for future clinical development.  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-25-008.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-25-008.html</a>	Up to \$300,000 per year, for up to 1 year (R61) Up to \$500,000 per year, for up to 3 years (R33)	Letter of intent: 2/29/24 Proposal: 3/29/24
		<b>SLEEP HEALTH (1)</b>		
73.	Pre-Announcement Sleep Health Topical PCORI Funding Announcement -- Cycle 1 2024 (PCORI)	This PFA will fund high-quality, comparative clinical effectiveness research (CER) projects that focus on sleep health. PCORI is particularly interested in applications focusing on sleep in high-need and/or underserved populations  <a href="https://www.pcori.org/funding-opportunities/announcement/sleep-health-topical-pcori-funding-announcement-cycle-1-2024">https://www.pcori.org/funding-opportunities/announcement/sleep-health-topical-pcori-funding-announcement-cycle-1-2024</a>	Up to \$12 million, for up to 5 years	System opens: 1/9/24 Letter of intent: 2/6/24 Proposal: 5/7/24
		<b>SMALL BUSINESS DEVELOPMENT (3)</b>		
74.	xTechSearch 8 (DoD/Army)	xTechSearch seeks novel, disruptive concepts and technology solutions with dual-use capabilities that can assist in tackling the Army's current needs and apply to current Army concepts. The intent is to provide the Army with transformative technology solutions while enabling cost savings throughout the Army systems' life cycle. Critical technology focus areas include artificial intelligence and machine learning; autonomy; climate and clean tech; contested logistics and sustainment; immersive and wearables; and sensors.  <a href="https://www.xtech.army.mil/competition/xtechsearch-8/">https://www.xtech.army.mil/competition/xtechsearch-8/</a>	Up to \$250,000	Proposal: 11/30/23
75.	Small Business Innovation Research (SBIR) Program Phase I (DoC/NIST)  2024-NIST-SBIR-01	Science and technology-based firms with strong research capabilities in any of the areas listed in Section 9.0 of this NOFO are encouraged to participate. NIST's research plays an essential role in health and bioscience innovations, including in precision medicine, engineering biology, medical imaging, regenerative medicine and our understanding of the microbiome and how it affects health. New and improved measurement capabilities advance our understanding of biology and provide the basis for industries to harness this information for future medical technologies.  <a href="https://www.grants.gov/search-results-detail/350700">https://www.grants.gov/search-results-detail/350700</a>	Up to \$100,000, for up to 6 months	Proposal: 12/22/23
76.	SBIR program, Phase I (HHS/ACL)  HHS-2024-ACL-NIDILRR-BISA-0069	The specific purpose of NIDILRR's SBIR program is to increase the commercial application of research and development results and improve the return on investment from research and development that can be used to improve the lives of individuals with disabilities.  <a href="https://www.grants.gov/search-results-detail/349378">https://www.grants.gov/search-results-detail/349378</a>	Up to \$100,000, for up to 6 months	Proposal: 12/18/23



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>SOCIAL DETERMINANTS OF HEALTH (1)</b>		
77.	Multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities (UG3/UH3, Clinical Trial Required) (NIH)  PAR-24-053	The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-053.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-053.html</a>	Up to \$500,000 per year, for up to 2 years (UG3) Up to \$750,000 per year, for up to 5 years (UH3)	Letter of intent: 7/5/24 Proposal: 8/5/24
		<b>SUBSTANCE USE DISORDER (5)</b>		
78.	Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional) (NIH/NIDA)  RFA-DA-25-058	There is an urgent need to develop novel treatments for SUD in light of the escalating rates of substance use, addiction, and overdose. Psychedelics may offer a new potential therapeutic use in SUD. Applications may include the evaluation of an existing psychedelic, a new formulation, or a new psychedelic compound. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-058.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-058.html</a>	Up to \$2 million per year, for up to 5 years	Letter of intent: 1/28/24 Proposal: 2/28/24
79.	Tools for Decentralized Clinical Trials for Substance Use Disorder (R41/R42/R43/R44 Clinical Trials Optional) (NIH/NIDA)  RFA-DA-25-051 (R41/R42) RFA-DA-25-052 (R43/R44)	These NOFOs encourage SBIR/STTR applications proposing research projects for developing tools for distributed clinical trials for substance use disorders (SUD). Applicants are encouraged to develop tools and/or software solutions that facilitate remote collection, transfer, handling and storage of relevant clinical data with the purpose of supporting distributed clinical trials for SUD. <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-051.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-051.html</a> (R41/R42) <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-052.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-052.html</a> (R43/R44)	Up to \$306,872 for 1 year (Phase I) Up to \$2,045,816 for up to 3 years (Phase II) <a href="#">Waiver topics</a> may exceed these amounts	Proposal: 3/14/24
80.	NOSI: Chemical Countermeasures Research Program (CCRP) Initiative: Additional Research Areas of Interest focusing on Ultra-Potent Synthetic (UPS) Opioids (NIH/NIDA/NIAID)  NOT-DA-23-044	The purpose of this NOSI is to solicit applications proposing basic research on Ultra-Potent Synthetic (UPS) opioids, alone or in combination with other substances, including xylazine. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DA-23-044.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DA-23-044.html</a>	Up to \$300,000 per year, for up to 3 years	Letter of intent: 10/19/24 Proposal: 11/19/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>SUBSTANCE USE DISORDER</b>		
81.	Pre-Announcement: Alcohol-associated Hepatitis Clinical Network – Late Phase Clinical Trials (NIH/NIAAA)  NOT-AA-24-001	The AlcHepNet cooperative program will include participating clinical sites and the Data Coordinating Center. The main focus of the network will be the conduct of an integrated treatment clinical trial that incorporates active treatment of Alcohol Use Disorder (AUD) with treatment of liver disease. <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-001.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AA-24-001.html</a>	TBD	Estimated post date: 1/3/24 Estimated proposal date: 3/5/24
		<b>THERAPEUTICS (2)</b>		
82.	Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3/U44 Clinical Trial Optional) (NIH)  PAR-24-043 (UG3/UH3) PAR-24-063 (U44)	The BPN invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-043.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-043.html</a> (UG3/UH3) <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-24-063.html">https://grants.nih.gov/grants/guide/pa-files/PAR-24-063.html</a> (U44)	Dependent upon proposal, for up to 5 years (UG3/UH3) Up to \$500,000 per year, for up to 2 years (Phase I) Up to \$1.5 million per year, for up to 3 years (Phase II) (U44)	Letter of intent: 1/9/24 Proposal: 2/9/24





# Recurring Opportunities

November 8, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)</b>		
83.	Open-Office Broad Agency Announcement (BAA)  75N99223S0001	Awardees will develop groundbreaking new ways to tackle health-related challenges through high-potential, high-impact biomedical and health research. ARPA-H has identified four initial focus areas that are a priority for investment: (1) Health Science Futures; (2) Scalable Solutions; (3) Proactive Health; (4) Resilient Systems.  <a href="https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view">https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view</a>	Dependent upon proposal and award mechanism	Abstract: 3/14/24
		<b>AIR FORCE (3)</b>		
84.	Airman Readiness Medical Research (ARMR) Hybrid BAA  FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332">https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332</a>	Up to \$49 million, per award	White papers accepted on rolling basis until 4/30/26
85.	Research Interests of the Air Force Office of Scientific Research  FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD).  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=345653">https://www.grants.gov/web/grants/view-opportunity.html?oppId=345653</a>	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>AIR FORCE</b>		
86.	Research Interests of the United States Air Force Academy  USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175">https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175</a>	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		<b>ARMY (8)</b>		
87.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB  CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems.  <a href="https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view">https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
88.	USAMRDC Broad Agency Announcement for Extramural Medical Research  HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725">https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725</a>	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
89.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development  HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=349586">https://www.grants.gov/web/grants/view-opportunity.html?oppld=349586</a>	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
90.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research  W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. <a href="#">Topics</a> include Biotronics, Genetics, and Neurophysiology of Cognition.  <a href="https://sam.gov/opp/e68f40ea3b224b86ab14b9d5a8af7f9c/view">https://sam.gov/opp/e68f40ea3b224b86ab14b9d5a8af7f9c/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>ARMY</b>		
91.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research  W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.  <a href="https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view">https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
92.	Army Applications Lab BAA for Disruptive Applications  W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517">https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517</a>	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
93.	Army Research Office Broad Agency Announcement Staff Research Program  W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences.  <a href="https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
94.	Army Combat Capabilities Development Command Broad Agency Announcement  W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285">https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		<b>BARDA (2)</b>		
95.	BARDA Broad Agency Announcement  BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; COVID-19 Immune Assay(s) Development and Implementation; Flexible and Strategic Therapeutics (FASTx).  <a href="https://sam.gov/opp/437e1da4c90345759330706d9391bebf/view">https://sam.gov/opp/437e1da4c90345759330706d9391bebf/view</a>	Dependent upon proposal	Proposal: 9/25/28





	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>BARDA</b>		
96.	BARDA DRIVe EZ-BAA <a href="#">DRIVeEZBAA22100SOL00003</a>	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #16: Lab at Home; AOI #17: Digital MCMs; AOI #19: Healing Lungs; AOI #24: REPAIR; AOI #25: FASTx; AOI #26: Agnostic Diagnostic. <a href="https://sam.gov/opp/79482f9236c64929938197ae21e9347a/view">https://sam.gov/opp/79482f9236c64929938197ae21e9347a/view</a>	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		<b>DARPA (2)</b>		
97.	Biological Technologies BAA <a href="#">HR001123S0045</a>	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. <a href="https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view">https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view</a>	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 6/20/24
98.	Defense Sciences Office, Office-wide <a href="#">HR001123S0053</a>	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. <a href="https://sam.gov/opp/972be70efd7e4608b01311466edf6bof/view">https://sam.gov/opp/972be70efd7e4608b01311466edf6bof/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/24
		<b>DEFENSE THREAT REDUCTION AGENCY (2)</b>		
99.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) <a href="#">HDTRA1-14-24-FRCWMD-BAA</a>	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. <a href="https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view">https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view</a>	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024
100.	Research and Development Innovations Broad Agency Announcement <a href="#">HDTRA1-22-S-0003</a>	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the <a href="#">2022 DTRA Strategic Plan for RDT&amp;E</a> : <ul style="list-style-type: none"> <li>• Understand current and emerging WMD situations, threats, and capabilities</li> <li>• Enable effective and integrated WMD deterrence</li> <li>• Control, disable, and defeat current and emerging WMD threats</li> <li>• Protect the force and mitigate crises from WMD</li> <li>• Enable cross-cutting capabilities</li> </ul> <a href="https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view">https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view</a>	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<b>DEPARTMENT OF ENERGY (1)</b>		
101.	FY 2024 Continuation of Solicitation for the Office of Science Financial Assistance Program  DE-FOA-0003177	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio.  <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppld=350408">https://www.grants.gov/web/grants/view-opportunity.html?oppld=350408</a>	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/24
		<b>NATIONAL SCIENCE FOUNDATION (1)</b>		
102.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I)  NSF 23-515	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. The NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required <a href="#">Project Pitch</a> allows applicants to get quick feedback. View the <a href="#">full list of topics</a> .  <a href="https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm">https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm</a>	Up to \$275,000 for up to 1 year	<a href="#">Project pitches</a> accepted on a rolling basis. Submission window for invited proposals: 7/6/23 to 1/9/24
		<b>NAVY (3)</b>		
103.	FY23 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies  N3943023S2501	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology.  <a href="https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view">https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view</a>	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/11/24
104.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology  N0001424SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations.  <a href="https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine">https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine</a>	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/24
105.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research  N00173-23-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2.  <a href="https://sam.gov/opp/ee708f6d2e244d0bb59d582c0362d9d1/view">https://sam.gov/opp/ee708f6d2e244d0bb59d582c0362d9d1/view</a>	Dependent upon proposal and award mechanism	White papers accepted through 12/29/23





### Terms

**AD/ADRD:** Alzheimer's Disease / Alzheimer's Disease Related Dementias

**Aoi:** Area of Interest

**BAA:** Broad Agency Announcement

**BBB:** Blood-Brain Barrier

**CNS:** Central Nervous System

**FOA:** Funding Opportunity Announcement

**IC:** NIH Institutes and Centers

**NOFO:** Notice of Funding Opportunity

**NOSI:** Notice of Special Interest

**PI:** Principal Investigator

**PTSD:** Post-Traumatic Stress Disorder

**RFI:** Request for Information

**RFP:** Request for Proposal

**SBIR:** Small Business Innovation Research

**SDOH:** Social Determinants of Health

**STTR:** Small Business Technology Transfer

**SUD:** Substance Use Disorder

**TRL:** Technology Readiness Level

**VCID:** Vascular Contributions to Cognitive Impairment and Dementia

### Agencies

**ARPA-H:** Advanced Research Projects Agency for Health

**ASPR:** Administration for Strategic Preparedness and Response

**BARDA:** Biomedical Advanced Research and Development Authority

**CDC:** Centers for Disease Control and Prevention

**CDMRP:** Congressionally Directed Medical Research Programs

**DARPA:** Defense Advanced Research Projects Agency

**DHA:** Defense Health Agency

**DoD:** Department of Defense

**FDA:** U.S. Food and Drug Administration

**MTEC:** Medical Technology Enterprise Consortium

**NIH:** National Institutes of Health

[Back to Table of Contents](#)

## GBG Acronyms

*Updated Monthly*

November 8, 2023

<https://www.g2gconsulting.com/gbg-reporting-service/>

**NSF:** National Science Foundation

**PCORI:** Patient-Centered Outcomes Research Institute

**USAMRDC:** U.S. Army Medical Research and Development Command

**USAMRIID:** U.S. Army Medical Research Institute of Infectious Diseases

**USSOCOM:** United States Special Operations Command

### NIH Institutes and Centers

**CC:** NIH Clinical Center

**CIT:** NIH Center for Information Technology

**CSR:** NIH Center for Scientific Review

**FIC:** Fogarty International Center

**NCATS:** National Center for Advancing Translational Sciences

**NCCIH:** National Center for Complementary and Integrative Health

**NCI:** National Cancer Institute

**NEI:** National Eye Institute

**NHGRI:** National Human Genome Research Institute

**NHLBI:** National Heart, Lung, and Blood Institute

**NIA:** National Institute on Aging

**NIAAA:** National Institute on Alcohol Abuse and Alcoholism

**NIAID:** National Institute of Allergy and Infectious Diseases

**NIAMS:** National Institute of Arthritis & Musculoskeletal & Skin Diseases

**NIBIB:** National Institute of Biomedical Imaging and Bioengineering

**NICHD:** Eunice Kennedy Shriver National Institute of Child Health and Human Development

**NIDA:** National Institute on Drug Abuse

**NIDCD:** National Institute on Deafness and Other Communication Disorders

**NIDCR:** National Institute of Dental and Craniofacial Research

**NIDDK:** National Institute of Diabetes and Digestive and Kidney Diseases

**NIEHS:** National Institute of Environmental Health Sciences

**NIGMS:** National Institute of General Medical Sciences

**NIMH:** National Institute of Mental Health

**NIMHD:** National Institute on Minority Health and Health Disparities

**NINDS:** National Institute of Neurological Disorders and Stroke

**NINR:** National Institute of Nursing Research

**NLM:** National Library of Medicine

